The Medical Letter on Drugs and Therapeutics
A Once-Yearly IV Bisphosphonate for Osteoporosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Zoledronic acid (Reclast – Novartis) is the first bisphosphonate approved by the FDA for once-yearly intravenous (IV) treatment of osteoporosis in postmenopausal women. Reclast is also approved for treatment of Paget’s disease. Another IV formulation of zoledronic acid (Zometa) is approved for treatment of hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors.1

BISPHOSPHONATES — Zoledronic acid is the second bisphosphonate (ibandronate was the first) approved for IV treatment of osteoporosis. Oral bisphosphonates can cause heartburn, esophageal irritation and esophagitis. To ensure adequate absorption (at best <1% is absorbed) and avoid esophageal injury, they must be taken after an overnight fast, while in an upright position, along with 8 ounces of plain (not mineral) water. After taking the drug, the patient must take nothing by ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Once-Yearly IV Bisphosphonate for Osteoporosis
Article code: 1273a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian